Effect of phosphate binders on supplemental iron absorption in healthy subjects.
A single-dose, prospective, randomized, four-treatment, four-period crossover study was conducted to determine the acute effect of therapeutically equivalent doses of three commonly used phosphate binders on oral iron absorption. Twenty-three healthy subjects received 65 mg of elemental iron alone and with each phosphate binder (calcium carbonate 3000 mg, calcium acetate 2668 mg, or sevelamer HCl 2821 mg). Area under the change in plasma iron concentration-time curve over 6 hours postdosing was measured. ANOVA was used to assess the statistical significance of differences in iron absorption among the treatments. The relative bioavailability of iron administered with each phosphate binder compared to iron administered alone was estimated. The relative iron bioavailabilities (95% confidence intervals) for the calcium carbonate, calcium acetate, and sevelamer HCI treatments were 0.81 (0.70, 0.94), 0.73 (0.63, 0.85), and 0.90 (0.78, 1.05), respectively. Thus, single doses of both calcium-based phosphate binders significantly reduced single-dose iron absorption, while sevelamer HCl did not.
D000085:Acetates / Q000494:pharmacology*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001682:Biological Availability; D002119:Calcium Carbonate / Q000494:pharmacology*; D017610:Calcium Compounds; D018592:Cross-Over Studies; D004347:Drug Interactions; D004852:Epoxy Compounds / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007501:Iron / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D010710:Phosphates / Q000378:metabolism*; D011073:Polyamines; D011095:Polyethylenes / Q000494:pharmacology*; D000069603:Sevelamer
D000085:Acetates; D017610:Calcium Compounds; D004852:Epoxy Compounds; D010710:Phosphates; D011073:Polyamines; D011095:Polyethylenes; D000069603:Sevelamer; D007501:Iron; D002119:Calcium Carbonate; C120662:calcium acetate